Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/27/2020 11/30/2020 12/01/2020 12/02/2020 12/03/2020 Date
144(c) 144.68(c) 147.45(c) 148.14(c) 149(c) Last
3 059 001 15 663 242 9 741 260 7 745 516 7 310 486 Volume
+0.22% +0.47% +1.91% +0.47% +0.58% Change
More quotes
Financials (USD)
Sales 2020 81 771 M - -
Net income 2020 15 967 M - -
Net Debt 2020 6 543 M - -
P/E ratio 2020 24,5x
Yield 2020 2,66%
Sales 2021 88 338 M - -
Net income 2021 18 332 M - -
Net cash position 2021 2 048 M - -
P/E ratio 2021 19,8x
Yield 2021 2,84%
Capitalization 392 B 392 B -
EV / Sales 2020 4,88x
EV / Sales 2021 4,42x
Nbr of Employees 132 200
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
01/26Earnings Release
More about the company
Notations Surperformance© of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
All news about JOHNSON & JOHNSON
12/03JOHNSON & JOHNSON : Janssen Headlines American Society of Hematology Annual Meet..
PU
12/03JOHNSON & JOHNSON : Change in Directors or Principal Officers (form 8-K)
AQ
12/03JOHNSON & JOHNSON : Names Dr. Nadja West, retired United States Army lieutenant ..
PR
12/03JOHNSON & JOHNSON : J&J Unit Seeks FDA OK of Amivantamab in Form of Non-Small Ce..
DJ
12/03JOHNSON & JOHNSON : Announces Fireside Chat Webcast on Janssen's Eye Disease Por..
PU
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
12/02HOFSETH BIOCARE ASA : HBC adds ex-Johnson & Johnson Senior Commercial leader, Wi..
AQ
12/01JOHNSON & JOHNSON : European Commission Approves Janssen's TREMFYA®▼ (guse..
PU
12/01JOHNSON & JOHNSON : New Survey Finds Critical Need for Education on Cataracts an..
PR
11/27Covid-19 Vaccine Studies May Suffer as Volunteers Consider Dropping Out
DJ
11/26JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - European Commission Appro..
AQ
11/25JOHNSON & JOHNSON : Pfizer, and Merck Lost $3.5B in Combined YTD Revenue
AQ
11/23JOHNSON & JOHNSON : Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supple..
PU
11/23JOHNSON & JOHNSON : Initiates Second Global Phase 3 Clinical Trial of its Jansse..
PU
More news
News in other languages on JOHNSON & JOHNSON
12/03++ Analysen des Tages von Dow Jones Newswires (03.12.2020) +++
12/03ANALYSE/Das Rennen um Covid-19-Impfstoffe beginnt gerade erst
12/02Nordkorea soll sechs Covid-Medikamentenentwickler attackiert haben
11/28SPOUTNIK V : pour les vaccins aussi, la Hongrie fait bande à part
11/26VACCINS CONTRE LE COVID-19 : un an de sprint, et l'espoir au bout
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 164,73 $
Last Close Price 149,00 $
Spread / Highest target 20,8%
Spread / Average Target 10,6%
Spread / Lowest Target -6,71%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033
ABBVIE INC.18.58%185 357